

**Amgen Inc.**  
**Reconciliation of GAAP earnings (loss) per share to "Adjusted" earnings per share**  
**(Unaudited)**

	Results for the quarters ended December 31,		Results for the years ended December 31,			
	2003	2004	2001	2002	2003	2004
<b>GAAP earnings (loss) per share</b> .....	\$ 0.41	\$ 0.53	\$ 1.03	\$ (1.21)	\$ 1.69	\$ 1.81
<b>Adjustments to GAAP earnings (loss) per share:</b>						
Write-off of acquired in-process research and development.....	-	-	-	2.53 (1)	-	0.42 (2)
Amortization of acquired intangible assets.....	0.04 (1)	0.04 (1)	-	0.12 (1)	0.17 (1)	0.16 (1)
Other merger-related expenses.....	0.01 (1)	0.01 (2)	-	0.06 (1)	0.04 (1)	0.02 (1) (2)
Legal settlement.....	-	-	-	-	0.02	(0.01)
Legal awards and cost recoveries.....	-	-	-	(0.12)	(0.04)	-
Amgen Foundation contribution.....	-	-	-	0.03	0.02	-
Termination of collaboration agreements.....	-	-	0.12	(0.03)	-	-
Other.....	-	-	0.03	-	-	-
	<u>0.46</u>	<u>0.58</u>	<u>1.18</u>	<u>1.38</u>	<u>1.90</u>	<u>2.40</u>
Adjustment for interest expense on convertible notes.....	-	-	-	0.01 (3)	-	-
<b>"Adjusted" earnings per share</b> .....	<u>\$ 0.46</u>	<u>\$ 0.58</u>	<u>\$ 1.18</u>	<u>\$ 1.39</u> (4)	<u>\$ 1.90</u>	<u>\$ 2.40</u>

**Notes:**

- (1) Incurred in connection with the Immunex Corporation acquisition in July 2002.
- (2) Incurred in connection with the Tularik Inc. acquisition in August 2004.
- (3) Pursuant to the if-converted method of calculating EPS, the numerator for "Adjusted" EPS in 2002 reflects the avoidance of interest expense incurred, net of tax, related to the assumed conversion of the convertible notes. The conversion of such debt and the avoidance of interest expense is not assumed for calculating the GAAP EPS because its impact is anti-dilutive due to the GAAP net loss in 2002.
- (4) Due to the GAAP net loss in 2002, shares used in calculating the GAAP loss per share exclude the impact of stock options and convertible notes because their impact was anti-dilutive. Shares used in calculating the "Adjusted" earnings per share for 2002 include the impact of dilutive stock options (27 million shares) and convertible notes (29 million shares) under the treasury stock and "if-converted" methods, respectively.

**Amgen Inc.**

**Reconciliation of GAAP earnings (loss) per share to "Adjusted" earnings per share  
(Unaudited)**

	Results for the years ended December 31,			
	2001	2002	2003	2004
<b>GAAP earnings (loss) per share</b> .....	\$ 1.03	\$ (1.21)	\$ 1.69	\$ 1.81
<b>Adjustments to GAAP earnings (loss) per share:</b>				
Write-off of acquired in-process research and development.....	-	2.53 (1)	-	0.42 (2)
Amortization of acquired intangible assets.....	-	0.12 (1)	0.17 (1)	0.16 (1)
Other merger-related expenses.....	-	0.06 (1)	0.04 (1)	0.02 (1)(2)
Legal settlement.....	-	-	0.02	(0.01)
Legal awards and cost recoveries.....	-	(0.12)	(0.04)	-
Amgen Foundation contribution.....	-	0.03	0.02	-
Termination of collaboration agreements.....	0.12	(0.03)	-	-
Other.....	0.03	-	-	-
	<u>1.18</u>	<u>1.38</u>	<u>1.90</u>	<u>2.40</u>
Adjustment for interest expense on convertible notes.....	-	0.01 (3)	-	-
<b>"Adjusted" earnings per share</b> .....	<u>\$ 1.18</u>	<u>\$ 1.39 (4)</u>	<u>\$ 1.90</u>	<u>\$ 2.40</u>

**Notes:**

- (1) Incurred in connection with the Immunex Corporation acquisition in July 2002.
- (2) Incurred in connection with the Tularik Inc. acquisition in August 2004.
- (3) Pursuant to the if-converted method of calculating EPS, the numerator for "Adjusted" EPS in 2002 reflects the avoidance of interest expense incurred, net of tax, related to the assumed conversion of the convertible notes. The conversion of such debt and the avoidance of interest expense is not assumed for calculating the GAAP EPS because its impact is anti-dilutive due to the GAAP net loss in 2002.
- (4) Due to the GAAP net loss in 2002, shares used in calculating the GAAP loss per share exclude the impact of stock options and convertible notes because their impact was anti-dilutive. Shares used in calculating the "Adjusted" earnings per share for 2002 include the impact of dilutive stock options (27 million shares) and convertible notes (29 million shares) under the treasury stock and "if-converted" methods, respectively.

Amgen Inc.  
Reconciliation of GAAP operating income (loss) to "Adjusted" operating income  
(In millions)  
(Unaudited)

	Results for the years ended December 31,			
	2001	2002	2003	2004
<b>GAAP operating income (loss)</b> .....	\$ 1,531	\$ (785)	\$ 3,091	\$ 3,348
<b>Adjustments to GAAP operating income (loss):</b>				
Write-off of acquired in-process research and development.....	-	2,992 (1)	-	554 (2)
Amortization of acquired intangible assets.....	-	155 (1)	336 (1)	333 (1)
Other merger-related expenses.....	-	87 (1)	70 (1)	53 (1) (2)
Legal settlement.....	-	-	47	(11)
Legal awards and cost recoveries.....	-	(151)	(74)	-
Amgen Foundation contribution.....	-	50	50	-
Termination of collaboration agreements.....	203	(40)	-	-
Other.....	40	-	-	-
<b>"Adjusted" operating income</b> .....	<u>\$ 1,774</u>	<u>\$ 2,308</u>	<u>\$ 3,520</u>	<u>\$ 4,277</u>

**Notes:**

- (1) Incurred in connection with the Immunex Corporation acquisition in July 2002.
- (2) Incurred in connection with the Tularik Inc. acquisition in August 2004.

**Amgen Inc.**

**Reconciliation of GAAP earnings (loss) per share Guidance to "Adjusted" earnings per share Guidance  
Guidance Provided in 2002 for the 2002-2005 period CAGR  
(Unaudited)**

	<b>Historical results for year ended 12/31/02</b>	<b>Implied results for year ended 12/31/05</b>
<b>GAAP (loss) earnings per share</b> .....	\$ (1.21)	\$2.55 - \$2.69
<b>Adjustments to GAAP (loss) earnings per share:</b>		
Write-off of acquired in-process research and development.....	2.53 (1)	-
Amortization of acquired intangible assets.....	0.12 (1)	0.16 (1)
Other merger related expenses.....	0.06 (1)	-
Legal award.....	(0.12)	-
Amgen Foundation contribution.....	0.03	-
Termination of collaboration agreements.....	(0.03)	-
	<u>1.38</u>	<u>2.71 - 2.85</u>
Adjustment for interest expense on convertible notes.....	<u>0.01 (2)</u>	<u>-</u>
<b>"Adjusted" earnings per share</b> .....	<u>\$ 1.39 (3)</u>	<u>\$2.71 - \$2.85</u>

Due to the GAAP loss per share of (\$1.21) in 2002, a GAAP EPS CAGR for the 2002-2005 period cannot be calculated.

The guidance for both "Adjusted" earnings per share and GAAP earnings per share does not include the impact of expense related to stock option compensation.

**Notes:**

- (1) Incurred in connection with the Immunex Corporation acquisition in July 2002.
- (2) Pursuant to the if-converted method of calculating EPS, the numerator for "Adjusted" EPS in 2002 reflects the avoidance of interest expense incurred, net of tax, related to the assumed conversion of the convertible notes. The conversion of such debt and the avoidance of interest expense is not assumed for calculating the GAAP EPS because its impact is anti-dilutive due to the GAAP net loss in 2002.
- (3) Due to the GAAP net loss in 2002, shares used in calculating the GAAP loss per share exclude the impact of stock options and convertible notes because their impact was anti-dilutive. Shares used in calculating the "Adjusted" earnings per share for 2002 include the impact of dilutive stock options (27 million shares) and convertible notes (29 million shares) under the treasury stock and "if-converted" methods, respectively.

**Amgen Inc.**

**Reconciliation of "Adjusted" Earnings Per Share Guidance to GAAP  
Earnings Per Share Guidance for the Year Ended December 31, 2005**

	<u>2005</u>
<b>"Adjusted" earnings per share guidance .....</b>	<b>\$ 2.70 - \$ 2.85</b>
<b>Known adjustments to arrive at GAAP earnings:</b>	
Amortization of acquired intangible assets (1) .....	(0.16)
Tularik merger related incremental compensation (2) .....	(0.01)
<b>GAAP earnings per share guidance .....</b>	<b><u>\$2.53 - \$2.68</u></b>

The guidance for both "Adjusted" earnings per share and GAAP earnings per share does not include the impact of expense related to stock option compensation.

- (1)** To exclude the ongoing, non-cash amortization of acquired intangible assets, primarily ENBREL®, related to the Immunex acquisition. The total annual non-cash charge is currently estimated to be approximately \$325 million, pre-tax.
- (2)** To exclude the incremental compensation provided to certain Tularik Inc. employees principally related to non-cash compensation expense associated with stock options assumed in connection with the acquisition and amounts payable under the Tularik Inc. short-term retention plan.